Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton F Stewart

Showing results (71-80 of 220) with videos related to

Pageof 22
Sort By:
Pharmaceutical Research|July 13, 2023
Using the LeiCNS-PK3.0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in MiceMohammed A A Saleh, Berfin Gülave, Olivia Campagne, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 7, 2013
Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS)Michael S Roberts, David C Turner, Thandranese S Owens, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2005
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTICMark N Kirstein, John C Panetta, Amar Gajjar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Population pharmacokinetic analysis of topotecan in pediatric cancer patientsPaula Schaiquevich, John C Panetta, Lisa C Iacono, et al.
Cancer Research|December 6, 2006
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitorYanli Zhuang, Charles H Fraga, K Elaine Hubbard, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 1, 2019
CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma modelOlivia Campagne, Abigail Davis, Anil R Maharaj, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumorsJohn C Panetta, Mark N Kirstein, Amar Gajjar, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 26, 2009
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)Feng Bai, Fangyi Zhu, Michael Tagen, et al.
Pediatric Blood & Cancer|September 4, 2023
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trialOlivia Campagne, Huiyun Wu, Jianrong Wu, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2010
Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluidAmit Khatri, M Waleed Gaber, Richard C Brundage, et al.
Pageof 22

Showing results (71-80 of 220) with videos related to

Sort By:
Pageof 22
Pharmaceutical Research|July 13, 2023
Using the LeiCNS-PK3.0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in MiceMohammed A A Saleh, Berfin Gülave, Olivia Campagne, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 7, 2013
Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS)Michael S Roberts, David C Turner, Thandranese S Owens, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2005
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTICMark N Kirstein, John C Panetta, Amar Gajjar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Population pharmacokinetic analysis of topotecan in pediatric cancer patientsPaula Schaiquevich, John C Panetta, Lisa C Iacono, et al.
Cancer Research|December 6, 2006
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitorYanli Zhuang, Charles H Fraga, K Elaine Hubbard, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 1, 2019
CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma modelOlivia Campagne, Abigail Davis, Anil R Maharaj, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumorsJohn C Panetta, Mark N Kirstein, Amar Gajjar, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 26, 2009
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)Feng Bai, Fangyi Zhu, Michael Tagen, et al.
Pediatric Blood & Cancer|September 4, 2023
Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trialOlivia Campagne, Huiyun Wu, Jianrong Wu, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2010
Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluidAmit Khatri, M Waleed Gaber, Richard C Brundage, et al.
Pageof 22